What is ozempic used for

FDA-Approved Uses

Ozempic (semaglutide) is a prescription medication in the GLP-1 receptor agonist class, first approved by the FDA in December 2017. Its primary FDA-approved indication is the treatment of type 2 diabetes mellitus to improve glycemic control (blood sugar levels). Additionally, the FDA approved Ozempic in 2020 to reduce the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adult patients with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. This cardiovascular benefit distinguishes Ozempic from some other diabetes medications.

How Ozempic Works

Ozempic works by mimicking glucagon-like peptide-1 (GLP-1), a natural hormone that regulates blood sugar. When blood glucose levels are high, semaglutide stimulates the pancreas to release insulin, reducing blood sugar. The medication also slows gastric emptying (stomach emptying), which keeps patients feeling full longer and reduces appetite. Additionally, GLP-1 receptors in the brain regulate hunger signals. These combined mechanisms make semaglutide effective for both blood sugar control and appetite suppression, though only the diabetes and cardiovascular uses are officially approved by the FDA.

Wegovy and Weight Loss

Wegovy is an FDA-approved weight management medication containing a higher dose of semaglutide (2.4 mg weekly compared to Ozempic's 0.5-1 mg weekly). The FDA approved Wegovy in June 2021 for chronic weight management in individuals with a BMI of 30 or higher, or 27 or higher with weight-related conditions. While Ozempic and Wegovy contain the same active ingredient, Wegovy is the only semaglutide formulation officially approved for weight loss. Due to supply shortages of Wegovy and its high cost, some physicians prescribe Ozempic off-label for weight loss, though this is not an FDA-approved use.

Side Effects and Tolerability

The most common side effects of Ozempic are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain. These effects are typically most pronounced when initiating treatment or increasing the dose, and often improve over time as the body adjusts. The reduced appetite caused by the medication can be severe for some patients. Rare but serious side effects include pancreatitis (inflammation of the pancreas), gallbladder problems, and thyroid tumors in animal studies. Patients with a personal or family history of medullary thyroid cancer should avoid semaglutide.

Availability and Prescribing

Ozempic is administered as a once-weekly subcutaneous injection that patients can self-administer at home. The medication requires a prescription from a healthcare provider. Due to high demand for weight loss purposes, shortages of both Ozempic and Wegovy have occurred, making these medications difficult to obtain. The cost can be substantial without insurance coverage, though many insurance plans cover Ozempic for diabetes management. Patients considering semaglutide should discuss potential benefits and risks with their healthcare provider to determine if it is appropriate for their specific situation.